Vimarsana
Biggest News Aggregation in the World

Page 10 - Safety Update News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Safety Update. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Safety Update Today - Breaking & Trending Today

Safety warning after sandbank causes strong rip current at Aberdeen beach - Vimarsana News

Safety warning after sandbank causes strong rip current at Aberdeen beach

Safety warning after sandbank causes strong rip current at Aberdeen beach Updated: 15/05/2021, 12:17 pm Aberdeen beach-goers have been warned to be aware of a strong rip current that has formed in a section of water there. A large sandbank has built up under the water at the Fittie end of the beach between the Highlander Cafe Bus and Burger King/The Range. This has caused water to flow at a higher speed through some of the deeper areas surrounding those two landmarks. ⚠️RNLI Local Safety Update – Footdee⚠️Over recent weeks we’ve become aware of a large sand bank which has built up...

PG&E : Reports First-Quarter 2021 Financial Results - Vimarsana News

PG&E : Reports First-Quarter 2021 Financial Results

PG&E Corporation Reports First-Quarter 2021 Financial Results •Recorded GAAP earnings were $0.06 per share for the first quarter of 2021, compared to earnings of $0.57 per share for the same period in 2020. •Non-GAAP core earnings were $0.23 per share for the first quarter of 2021, compared to $0.89 per share for the same period in 2020. •2021 EPS guidance adjusted for GAAP earnings in the range of $0.07 to $0.21and reaffirmed non-GAAP core earnings of $0.95 to $1.05 per share. SAN FRANCISCO - PG&E Corporation (NYSE: PCG) recorded first-quarter 2021 income ...

Number of COVID vaccine injuries reported to VAERS surpasses 50,000, CDC data show - Vimarsana News

Number of COVID vaccine injuries reported to VAERS surpasses 50,000, CDC data show

Number of COVID vaccine injuries reported to VAERS surpasses 50,000, CDC data show Data released today by the Centers for Disease Control and Prevention (CDC) on the number of injuries and deaths reported to the Vaccine Adverse Event Reporting System (VAERS) following COVID vaccines revealed steadily rising numbers, but no new trends. VAERS is the primary mechanism for reporting adverse vaccine reactions in the U.S. Reports submitted to VAERS require further investigation before a causal relationship can be confirmed. Every Friday, VAERS makes public all vaccine injury reports received to the...

Software As A Medical Device In Europe – New Regulatory Regime About To Enter Into Force – (Part 4 Of 6) | MoFo Life Sciences - Vimarsana News

Software As A Medical Device In Europe – New Regulatory Regime About To Enter Into Force – (Part 4 Of 6) | MoFo Life Sciences

To embed, copy and paste the code into your website or blog: After having dealt with the issue when software may be considered a medical device according to its intended purpose (in part 2) and the implications of the new risk classification regime (in part 3), in this part 4 of our series on Software as a Medical Device in Europe, we will now explore key changes to the quality assurance and documentation requirements for stand-alone medical device software (“ MDR”). INTRODUCTION: A NEW LIFE CYCLE-FOCUSED APPROACH MDD”) primarily focusses on the pre-approval stage of a medical device...

REGENXBIO Announces Additional Positive Interim Phase I/IIa and Long-Term Follow-Up Data of RGX-314 for the Treatment of Wet AMD - Vimarsana News

REGENXBIO Announces Additional Positive Interim Phase I/IIa and Long-Term Follow-Up Data of RGX-314 for the Treatment of Wet AMD

RGX-314 using subretinal delivery continues to be generally well-tolerated at all dose levels Positive interim update from Cohorts 4 and 5 at 1.5 years after RGX-314 administration Durable treatment effect observed with stable visual acuity, decreased retinal thickness, and reductions in anti-VEGF injection burden Long-term, durable treatment effect over three years demonstrated in Cohort 3 Mean improvement in vision and stable retinal thickness 50% of patients (3/6) remain anti-VEGF injection-free over three years; 67% of patients (4/6) are anti-VEGF injection-free from nine months to th...